Immune Microenvironment in Langerhans Cell Histiocytosis: Potential Prognostic Indicators
Open Access
- 7 May 2021
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Oncology
Abstract
In this study, the immune microenvironment in Langerhans cell histiocytosis (LCH) was characterized to determine if immune indices are predictive of severity. Serum samples from 54 treatment-naïve patients were analyzed quantitatively for inflammatory cytokines and immunoglobulins before and after the induction of chemotherapy. The initial serum sIL-2R, TNF-α, and IL-10 of untreated LCH patients with risk organ involvement (RO+) were significantly higher than those with single-system (SS) involvement. LCH patients with hematologic involvement exhibited a significantly higher sIL-2R, TNF-α, IL-10, and IL-1β expression, as compared to the group without involvement. sIL-2R, TNF-α, and IL-10 were increased in patients with liver or spleen involvement. Th cells have decreased in the liver+ and spleen+ group, and Ts cells were significantly decreased in non-response group after induction chemotherapy. The serum level of immune indices represents, to some extent, the severity of the disease. Pertinent laboratory inspections can be used to improve risk stratification and guide immunotherapy.This publication has 25 references indexed in Scilit:
- BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groupsThe Journal of Experimental Medicine, 2015
- Activating BRAF V600E Mutation in Aggressive Pediatric Langerhans Cell HistiocytosisThe American Journal of Surgical Pathology, 2014
- Potential clinical implications ofBRAFmutations in histiocytic proliferationsOncotarget, 2014
- Recent advances in Langerhans cell histiocytosisPediatrics International, 2014
- BRAF V600E Expression in Langerhans Cell HistiocytosisThe American Journal of Surgical Pathology, 2014
- Oncogene-induced senescence distinguishes indolent from aggressive forms of pulmonary and non-pulmonary Langerhans cell histiocytosisLeukemia & Lymphoma, 2014
- High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytosesBlood, 2012
- BRAFV600E mutant protein is expressed in cells of variable maturation in Langerhans cell histiocytosisBlood, 2012
- B-RAF Mutant Alleles Associated with Langerhans Cell Histiocytosis, a Granulomatous Pediatric DiseasePLOS ONE, 2012
- Recurrent BRAF mutations in Langerhans cell histiocytosisBlood, 2010